Towards safer anti-inflammatory therapy: synthesis of new thymol–pyrazole hybrids as dual COX-2/5-LOX inhibitors
作者:Mostafa M. M. El-Miligy、Ahmed K. Al-Kubeisi、Mohamed G. Bekhit、Saad R. El-Zemity、Rasha A. Nassra、Aly A. Hazzaa
DOI:10.1080/14756366.2022.2147164
日期:2023.1.1
Abstract New thymol − 1,5-disubstitutedpyrazole hybrids were synthesised as dual COX-2/5-LOX inhibitors. Compounds 8b, 8g, 8c, and 4a displayed in vitro inhibitory activity against COX-2 (IC50 = 0.043, 0.045, 0.063, and 0.068 µM) nearly equal to celecoxib (IC50 = 0.045 µM) with high SI (316, 268, 204, and 151, respectively) comparable to celecoxib (327). All target compounds, 4a–c and 8a–i, showed
摘要 新的百里酚 − 1,5-二取代吡唑杂化物被合成为双重 COX-2/5-LOX 抑制剂。化合物8b、8g、8c和4a对 COX-2的体外抑制活性(IC 50 = 0.043、0.045、0.063和 0.068 µM )几乎等于塞来昔布(IC 50 = 0.045 µM ),具有高 SI(316、268 ) 、204 和 151)与塞来昔布 (327) 相当。所有目标化合物4a–c和8a–i均显示出高于参考槲皮素的体外5-LOX 抑制活性。此外,他们还拥有体内对福尔马林引起的爪水肿的抑制作用高于塞来昔布。此外,化合物4a、4b、8b和8g在禁食大鼠群体中表现出优于塞来昔布和双氯芬酸钠的胃肠道安全性特征(无溃疡)。总之,化合物4a、8b和8g达到了目标。它们在体外引起比塞来昔布和槲皮素更高的 COX-2/5-LOX 双重抑制,比塞来昔布更高的体内抗炎活性和比塞来昔布更高的体内胃肠道安全性(无溃疡)。